RTKN2

Across TCGA pan-cancer cohorts, RTKN2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RTKN2 data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher RTKN2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RTKN2 expression acts as an unfavorable survival marker.

STAD, COAD, and CESC are the cancer types where RTKN2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	All	0.179	0.634	.001	36	view →
COAD	OS	Median	All	0.178	0.681	<.001	14	view →
CESC	DFS	Median	II,III,IV	0.140	0.785	<.001	12	view →
LIHC	DFS	Median	All	0.081	0.527	.012	12	view →
BLCA	OS	Median	IV	0.250	0.602	.033	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RTKN2–STAD (DFS)

Open the STAD breakdown →